NO20074497L - Synergistisk kombinasjon av xolair/omalizumab/E25 med immunsuppressivt middel - Google Patents
Synergistisk kombinasjon av xolair/omalizumab/E25 med immunsuppressivt middelInfo
- Publication number
- NO20074497L NO20074497L NO20074497A NO20074497A NO20074497L NO 20074497 L NO20074497 L NO 20074497L NO 20074497 A NO20074497 A NO 20074497A NO 20074497 A NO20074497 A NO 20074497A NO 20074497 L NO20074497 L NO 20074497L
- Authority
- NO
- Norway
- Prior art keywords
- xolair
- omalizumab
- immunosuppressant
- synergistic combination
- pharmaceutically acceptable
- Prior art date
Links
- 239000003018 immunosuppressive agent Substances 0.000 title abstract 2
- 229960003444 immunosuppressant agent Drugs 0.000 title 1
- 230000001861 immunosuppressant effect Effects 0.000 title 1
- 229960000470 omalizumab Drugs 0.000 title 1
- 239000011885 synergistic combination Substances 0.000 title 1
- 229940099073 xolair Drugs 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229940125721 immunosuppressive agent Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0502358.5A GB0502358D0 (en) | 2005-02-04 | 2005-02-04 | Organic compounds |
| PCT/EP2006/000911 WO2006082052A1 (fr) | 2005-02-04 | 2006-02-02 | Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20074497L true NO20074497L (no) | 2007-10-26 |
Family
ID=34355808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20074497A NO20074497L (no) | 2005-02-04 | 2007-09-04 | Synergistisk kombinasjon av xolair/omalizumab/E25 med immunsuppressivt middel |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20080206237A1 (fr) |
| EP (1) | EP1846031A1 (fr) |
| JP (1) | JP2008528650A (fr) |
| KR (1) | KR20070100344A (fr) |
| CN (1) | CN101111265A (fr) |
| AR (1) | AR053541A1 (fr) |
| AU (1) | AU2006210098A1 (fr) |
| BR (1) | BRPI0607349A2 (fr) |
| CA (1) | CA2595976A1 (fr) |
| GB (1) | GB0502358D0 (fr) |
| GT (1) | GT200600023A (fr) |
| IL (1) | IL184713A0 (fr) |
| MA (1) | MA29273B1 (fr) |
| MX (1) | MX2007009436A (fr) |
| NO (1) | NO20074497L (fr) |
| PE (1) | PE20061203A1 (fr) |
| RU (1) | RU2007132980A (fr) |
| TN (1) | TNSN07304A1 (fr) |
| TW (1) | TW200640487A (fr) |
| WO (1) | WO2006082052A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2595960A1 (fr) * | 2005-02-08 | 2006-08-17 | Novartis Ag | Induction d'un anticorps antilymphocyte |
| PT2708559T (pt) | 2008-04-11 | 2018-05-16 | Chugai Pharmaceutical Co Ltd | Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio |
| PL2853545T3 (pl) * | 2008-09-17 | 2016-12-30 | Przeciwciało swoiste wobec IgE | |
| MA33930B1 (fr) * | 2009-12-18 | 2013-01-02 | Sanofi Sa | Nouveaux anticorps antagonistes contre gpvi et leurs fragments fab et utilisations de ceux-ci |
| MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
| EP3604330A1 (fr) | 2011-02-25 | 2020-02-05 | Chugai Seiyaku Kabushiki Kaisha | Anticorps fc spécifique au fcgammariib |
| JO3177B1 (ar) * | 2011-04-01 | 2018-03-08 | Novartis Ag | تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول |
| EP2762493B1 (fr) | 2011-09-30 | 2021-06-09 | Chugai Seiyaku Kabushiki Kaisha | Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| HUE056489T2 (hu) | 2014-12-19 | 2022-02-28 | Chugai Pharmaceutical Co Ltd | Anti-C5 antitestek és alkalmazási eljárások |
| SG11201706014PA (en) | 2015-02-05 | 2017-08-30 | Chugai Pharmaceutical Co Ltd | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| SG11201705093UA (en) | 2015-02-27 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Composition for treating il-6-related diseases |
| WO2017106859A1 (fr) | 2015-12-18 | 2017-06-22 | University Of Notre Dame Du Lac | Inhibiteurs d'anticorps hétérobivalents covalents et ligands |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
| KR102538749B1 (ko) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| WO2018139623A1 (fr) | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anticorps anti-sclérostine et procédés d'utilisation |
| JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
| DE102017215154A1 (de) | 2017-08-30 | 2019-02-28 | Markus Bläss | Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen |
| US12030959B1 (en) | 2023-07-05 | 2024-07-09 | Genentech, Inc. | Anti-IgE antibody therapy for multiple food allergies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
| GB0200429D0 (en) * | 2002-01-09 | 2002-02-27 | Novartis Ag | Organic compounds |
-
2005
- 2005-02-04 GB GBGB0502358.5A patent/GB0502358D0/en not_active Ceased
-
2006
- 2006-01-18 GT GT200600023A patent/GT200600023A/es unknown
- 2006-02-02 BR BRPI0607349-2A patent/BRPI0607349A2/pt not_active Application Discontinuation
- 2006-02-02 EP EP06706581A patent/EP1846031A1/fr not_active Withdrawn
- 2006-02-02 WO PCT/EP2006/000911 patent/WO2006082052A1/fr not_active Ceased
- 2006-02-02 AR ARP060100378A patent/AR053541A1/es not_active Application Discontinuation
- 2006-02-02 CN CNA2006800039151A patent/CN101111265A/zh active Pending
- 2006-02-02 CA CA002595976A patent/CA2595976A1/fr not_active Abandoned
- 2006-02-02 US US11/814,871 patent/US20080206237A1/en not_active Abandoned
- 2006-02-02 AU AU2006210098A patent/AU2006210098A1/en not_active Abandoned
- 2006-02-02 KR KR1020077017947A patent/KR20070100344A/ko not_active Withdrawn
- 2006-02-02 MX MX2007009436A patent/MX2007009436A/es not_active Application Discontinuation
- 2006-02-02 PE PE2006000134A patent/PE20061203A1/es not_active Application Discontinuation
- 2006-02-02 JP JP2007553536A patent/JP2008528650A/ja active Pending
- 2006-02-02 RU RU2007132980/13A patent/RU2007132980A/ru not_active Application Discontinuation
- 2006-02-03 TW TW095103825A patent/TW200640487A/zh unknown
-
2007
- 2007-07-19 IL IL184713A patent/IL184713A0/en unknown
- 2007-08-03 TN TNP2007000304A patent/TNSN07304A1/en unknown
- 2007-08-28 MA MA30171A patent/MA29273B1/fr unknown
- 2007-09-04 NO NO20074497A patent/NO20074497L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1846031A1 (fr) | 2007-10-24 |
| MX2007009436A (es) | 2007-08-17 |
| CA2595976A1 (fr) | 2006-08-10 |
| AR053541A1 (es) | 2007-05-09 |
| JP2008528650A (ja) | 2008-07-31 |
| AU2006210098A1 (en) | 2006-08-10 |
| CN101111265A (zh) | 2008-01-23 |
| PE20061203A1 (es) | 2006-12-19 |
| GB0502358D0 (en) | 2005-03-16 |
| MA29273B1 (fr) | 2008-02-01 |
| TW200640487A (en) | 2006-12-01 |
| US20080206237A1 (en) | 2008-08-28 |
| IL184713A0 (en) | 2007-12-03 |
| BRPI0607349A2 (pt) | 2009-09-01 |
| WO2006082052A1 (fr) | 2006-08-10 |
| KR20070100344A (ko) | 2007-10-10 |
| RU2007132980A (ru) | 2009-03-10 |
| GT200600023A (es) | 2006-08-16 |
| TNSN07304A1 (en) | 2008-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20074497L (no) | Synergistisk kombinasjon av xolair/omalizumab/E25 med immunsuppressivt middel | |
| Fulton et al. | Mycophenolate mofetil: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation | |
| CY1114594T1 (el) | Χρηση της [d-meala]3[etval]4-κυκλοσπορινης για την θεραπεια μολυνσης απο ηπατιτιδα c και φαρμακευτικη συνθεση που περιλαμβανει την εν λογω [d-meala]3[etval]4-κυκλοσπορινη | |
| TW200700406A (en) | Novel thiophene derivatives | |
| TW200716591A (en) | Novel thiophene derivatives | |
| NO20084882L (no) | Krystallinske former A og B av et maleatsalt av 5-amino-3-(2'3'-di-o-acetyl-beta-D-ribofuranosyl)-3H-tiazolo[4,5-d] pyrimidin-2 on | |
| TW200708511A (en) | Novel thiophene derivatives | |
| IL192948A0 (en) | Novel pyridine derivatives | |
| TW200716552A (en) | Novel thiophene derivatives | |
| BRPI0416752B8 (pt) | composição farmacêutica, uso de um ou mais compostos, e, compostos | |
| CL2004000930A1 (es) | Compuesto derivado de dihidroquinazolina de formula definida, util para el tratamiento y/o profilaxis de infecciones virales; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de medicamentos. | |
| DK1356052T3 (da) | Produktion af hele antistoffer i prokaryotiske celler | |
| MX2007000023A (es) | Anticuerpos del receptor uno de interferon alfa, y sus usos. | |
| TW200738670A (en) | Novel thiophene derivatives | |
| ECSP066756A (es) | Anticuerpo monoclonal específico m-csf y los usos del mismo | |
| NO20070073L (no) | Pyrazolderivater, preparater inneholdende disse og metoder for anvendelse derav | |
| WO2007016285A3 (fr) | Anticorps monoclonal specifique de m-csf et ses utilisations | |
| MY149306A (en) | Solid preparation containing an insulin sensitizer | |
| ATE513555T1 (de) | Pharmazeutische kombination aus g-csf und plgf für blutstammzellen | |
| WO2004029214A3 (fr) | Anticorps lies a la sous-unite alpha de lfa-1 et methodes d'utilisation | |
| WO2007120156A3 (fr) | Modeles animaux du syndrome du qt long congenital et leurs utilisations | |
| JP2006527741A5 (fr) | ||
| DE102006035083A8 (de) | Proteinbindende Methotrexat-Derivate und diese enthaltende Arzneimittel | |
| Qi et al. | Malononitrilamides 715 and 279 prolong rat cardiac allograft survival, reverse ongoing rejection, inhibit allospecific antibody production and interact positively with cyclosporin. | |
| WO2006012958A3 (fr) | Combinaison comprenant un inhibiteur bcrp et 4-(4-methylpiperazine-1-ylmethyle)-n-[4-methyl-3-(4-pyridine-3-yl)pyrimidine-2-ylamino)phenyle]-benzamide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |